Showing results (201-210 of 270) with videos related to

Sort By:
Pageof 27
JCO Precision Oncology|January 30, 2023
Benchmarking Outcomes for Molecularly Characterized Synchronous Oligometastatic Non-Small-Cell Lung Cancer Reveals EGFR Mutations to Be Associated With Longer Overall SurvivalBrian De, Ahsan S Farooqi, Kyle G Mitchell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2022
Induction chemotherapy with or without erlotinib in patients with head and neck squamous cell carcinoma amenable for surgical resectionXiuning Le, Frederico O Gleber-Netto, M Laura Rubin, et al.
Cancer Innovation|July 1, 2024
Integrative genomic and transcriptomic profiling of pulmonary sarcomatoid carcinoma identifies molecular subtypes associated with distinct immune features and clinical outcomesSahil Seth, Runzhe Chen, Yang Liu, et al.
Plos One|November 17, 2015
Isolation and Characterization of Circulating Tumor Cells in Squamous Cell Carcinoma of the Lung Using a Non-EpCAM-Based Capture MethodCecilia Bozzetti, Federico Quaini, Anna Squadrilli, et al.
Lung Cancer (Amsterdam, Netherlands)|November 15, 2022
Pralsetinib in RET fusion-positive non-small-cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (EAP)Antonio Passaro, Giuseppe Lo Russo, Francesco Passiglia, et al.
Oncogene|December 14, 2019
Correction: Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutationYing Jin, Hua Bao, Xiuning Le, et al.
Oncogene|November 23, 2019
Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutationYing Jin, Hua Bao, Xiuning Le, et al.
JTO Clinical and Research Reports|August 31, 2023
Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLCKaiwen Wang, Robyn Du, Sinchita Roy-Chowdhuri, et al.
Nature Communications|September 24, 2025
Poziotinib for EGFR exon 20-insertion NSCLC: Clinical efficacy of the phase 2 ZENITH trial and differential impact of EGFR exon 20 insertion location on sensitivityXiuning Le, Jacqulyne P Robichaux, Monique Nilsson, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 2, 2024
Receptor Tyrosine Kinase Fusion-Mediated Resistance to EGFR TKI in EGFR-Mutant NSCLC: A Multi-Center Analysis and Literature ReviewYang Xia, Kaiwen Wang, Jing Zhao, et al.
Pageof 27